PHS
DXCM icon

PFM Health Sciences’s DexCom DXCM Stock Holding History

PFM Health Sciences’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.4M Sell
149,734
-77,623
-34% -$5.41M 0.86% 39
2025
Q4 		$15.1M Buy
+227,357
New +$14.7M 1.5% 25
2025
Q1 		– Sell
-328,763
Closed -$25.6M – 73
2024
Q4 		$25.6M Buy
+328,763
New +$24.3M 1.58% 20
2024
Q3 		– Sell
-231,007
Closed -$26.2M – 78
2024
Q2 		$26.2M Buy
231,007
+75,129
+48% +$9.5M 1.3% 29
2024
Q1 		$21.6M Buy
+155,878
New +$19.6M 1.02% 34
2023
Q4 		– Sell
-318,769
Closed -$29.7M – 70
2023
Q3 		$29.7M Sell
318,769
-55,709
-15% -$6.28M 1.4% 32
2023
Q2 		$48.1M Sell
374,478
-49,338
-12% -$5.97M 1.87% 20
2023
Q1 		$49.2M Buy
423,816
+288,351
+213% +$32.3M 2.17% 11
2022
Q4 		$15.3M Buy
+135,465
New +$14.9M 0.55% 61
2022
Q2 		– Sell
-148,084
Closed -$18.9M – 81
2022
Q1 		$18.9M Buy
148,084
+130,208
+728% +$14.2M 0.71% 48
2021
Q4 		$2.4M Sell
17,876
-52,164
-74% -$7.5M 0.08% 69
2021
Q3 		$9.58M Buy
+70,040
New +$8.83M 0.28% 64
2021
Q2 		– Sell
-225,768
Closed -$20.3M – 89
2021
Q1 		$20.3M Buy
+225,768
New +$21.2M 0.62% 53
2019
Q4 		– Sell
-1,712,968
Closed -$63.9M – 63
2019
Q3 		$63.9M Buy
1,712,968
+66,184
+4% +$2.57M 1.89% 17
2019
Q2 		$61.7M Buy
+1,646,784
New +$51.8M 1.17% 26
2018
Q4 		– Sell
-1,221,216
Closed -$43.7M – 101
2018
Q3 		$43.7M Buy
+1,221,216
New +$37.9M 0.64% 59
2018
Q2 		– Sell
-2,056,656
Closed -$38.1M – 119
2018
Q1 		$38.1M Buy
+2,056,656
New +$30.4M 0.77% 54
2016
Q2 		– Sell
-682,140
Closed -$11.6M – 86
2016
Q1 		$11.6M Sell
682,140
-22,012
-3% -$368K 0.36% 66
2015
Q4 		$14.4M Buy
+704,152
New +$14.7M 0.44% 51

Other funds holding DXCM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PFM Health Sciences's DXCM Position: Q1 2026 in Review

PFM Health Sciences reduced its DexCom (DXCM) stake by 34% in Q1 2026, selling an estimated $5.41M and leaving 149,734 shares worth $9.4M. The position accounts for 0.86% of the portfolio, ranked #39.

PFM Health Sciences first reported a position in DXCM in Q4 2015 and has held it in 19 quarters since. The position peaked at $63.9M in Q3 2019. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • PFM Health Sciences held 149,734 shares of DexCom worth $9.4M as of Q1 2026.
  • PFM Health Sciences sold 77,623 DexCom shares in Q1 2026, an estimated $5.41M.
  • DexCom made up 0.86% of PFM Health Sciences's portfolio in Q1 2026, its #39 holding.
  • PFM Health Sciences first reported a position in DexCom in Q4 2015 and has held it in 19 quarters since.
  • PFM Health Sciences's DexCom position peaked at $63.9M in Q3 2019.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.